A Look At IDEAYA Biosciences (IDYA) Valuation After Darovasertib OptimUM-02 And Pipeline Updates
IDEAYA Biosciences (IDYA) is under valuation scrutiny after reporting positive OptimUM-02 trial data for darovasertib, showing longer median progression-free survival for its lead melanoma drug. While the company's P/S ratio of 11.6x appears expensive compared to the industry average, a Discounted Cash Flow (DCF) model suggests the stock is undervalued, leading to mixed signals on its current worth. Investors are encouraged to assess the full risk-reward picture, considering trial setbacks and ongoing losses due to pipeline development, despite strong longer-term momentum reflected in a 54.83% one-year total shareholder return.
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
IDEAYA Biosciences announced that its lead melanoma drug, darovasertib, is on track for an NDA submission following positive OptimUM-02 clinical trial data showing significantly improved progression-free survival in first-line metastatic melanoma. The company plans to present more comprehensive data, including efficacy, imaging, and safety, at ASCO. IDEAYA is also advancing other pipeline programs, including IDE849 for small cell lung cancer and neuroendocrine carcinoma, with registrational studies planned by year-end.
Will Widened Q1 Loss and New Shelf Registration Change IDEAYA Biosciences’ (IDYA) Funding Narrative?
IDEAYA Biosciences reported a widened Q1 2026 net loss of US$98.54 million alongside US$6.56 million in revenue, and has filed an omnibus shelf registration for various securities. This move highlights the company's focus on funding flexibility for its precision oncology pipeline, particularly darovasertib. While the shelf registration offers capital-raising options, it also introduces potential for future dilution, making financial risk a key factor for investors to monitor closely.
Janus Henderson holds 7.27M IDEAYA shares (NASDAQ: IDYA)
Janus Henderson Group plc has reported beneficial ownership of 7,265,253 shares of IDEAYA Biosciences, Inc. common stock, representing 8.3% of the class as of March 31, 2026. This position is held through multiple asset managers, who exercise shared voting and dispositive power on behalf of managed client accounts. The filing clarifies that the asset managers disclaim rights to dividends or sale proceeds associated with this ownership, and no single managed portfolio owns more than 5% of IDEAYA.
Ideaya Biosciences stock (US45166A1025): Minor price dip amid biotech hiring push
Ideaya Biosciences (IDYA) shares experienced a minor dip of 0.0355% to $28.12 on May 12, 2026, despite the clinical-stage biotech actively expanding its workforce with nearly 20 new roles in California. The company, focused on precision oncology, is advancing its pipeline with programs like IDE397 and darovasertib, using AI-driven drug discovery. Technical analysis indicates buy signals for IDYA, suggesting continued investor interest in its growth trajectory within the competitive US biotech landscape.
Precision Trading with Ideaya Biosciences Inc. (IDYA) Risk Zones
This article from Stock Traders Daily provides a risk analysis for Ideaya Biosciences Inc. (IDYA) based on AI models. It highlights divergent sentiment across different time horizons, suggesting choppy conditions for the stock, and identifies elevated downside risk. The analysis includes specific position trading, momentum breakout, and risk hedging strategies, along with support and resistance signals.
Ideaya Biosciences stock (US45166A1025): Positioned in iShares Genomics ETF holdings
Ideaya Biosciences (IDYA) is a clinical-stage precision oncology company focused on synthetic lethality-based therapies. It holds a significant position in the iShares Genomics Immunology and Healthcare ETF (IDNA) with a 2.61% weighting, reflecting investor interest in its pipeline. The company's strategy involves leveraging proprietary technologies to identify tumor vulnerabilities and advance therapies like IDE397 and darovasertib, with future revenue tied to clinical outcomes and partnerships.
Vanguard Group Inc. Buys 97,116 Shares of IDEAYA Biosciences, Inc. $IDYA
Vanguard Group Inc. increased its stake in IDEAYA Biosciences (NASDAQ:IDYA) by 2.0% in the fourth quarter, purchasing an additional 97,116 shares to bring its total holdings to over 5 million shares valued at approximately $173.5 million. Despite the company reporting a wider-than-expected quarterly loss of ($1.11) per share, its revenue of $6.56 million surpassed Wall Street estimates. Analysts maintain a generally positive outlook on the stock, with an average price target significantly higher than its current trading price.
Time To Worry? Analysts Are Downgrading Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Outlook
Analysts have recently downgraded their outlook for IDEAYA Biosciences, Inc. (IDYA), revising their revenue forecasts downward for the coming fiscal years. The consensus price target for IDYA has also seen a modest reduction, indicating a slightly less optimistic future. Despite these revisions, the average price target still suggests significant upside potential from the current share price.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates
IDEAYA Biosciences (NASDAQ:IDYA) recently reported first-quarter results, with shares falling 3.0% post-announcement. While revenues exceeded analyst expectations by 30%, statutory losses were 12% higher than anticipated. Analysts have subsequently cut 2026 revenue estimates significantly and increased loss per share forecasts, though the consensus price target remained largely unchanged.
Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates
Analysts have downgraded their revenue forecasts for IDEAYA Biosciences, Inc. (IDYA) for the current year, leading to an expected 88% decline in sales and increased per-share losses. Despite the significant cut to revenue estimates and a rise in anticipated losses, the consensus price target remained unchanged. The company's revenues are projected to shrink by 94% by the end of 2026, lagging behind the wider industry's expected growth.
Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates
Analysts have downgraded their forecasts for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) this year, with a significant cut to revenue estimates and an expected increase in per-share losses. The revised consensus predicts revenues of US$27m for 2026, an 88% decline, and losses of US$4.29 per share, up from a previous estimate of US$4.03. This indicates that sales are expected to slow considerably and lag behind the broader industry growth.
Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates
Analysts have significantly downgraded IDEAYA Biosciences, Inc.'s revenue and increased loss per share estimates for 2026, implying an 88% decline in sales and a higher per-share loss of US$4.29. The consensus price target remained unchanged, but the company's projected revenue decline of 94% by the end of 2026 is expected to significantly underperform the broader industry. This substantial downgrade suggests potential caution from the market regarding IDEAYA Biosciences' future performance.
IDYA SEC Filings - Ideaya Biosciences 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Ideaya Biosciences (IDYA) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details the company's regulatory disclosures, such as material events, financial results, collaborations, and governance decisions, with recent examples like board compensation stock options and shareholder voting results. The platform also offers AI-powered summaries to help investors understand the significance of each document.
Ideaya Biosciences Inc Files For Mixed Shelf Offering, Size Not Disclosed- SEC Filing
Ideaya Biosciences Inc has filed for a mixed shelf offering with the SEC. The size of the offering has not been disclosed. This filing indicates the company's intention to potentially raise capital in the future by offering a variety of securities.
IDEAYA Biosciences (IDYA) Persistent Losses Challenge Bullish High Revenue Growth Narratives
IDEAYA Biosciences (IDYA) reported Q1 2026 results with a net loss of US$83.3 million, despite revenue swings tied to one-off deals, demonstrating persistent unprofitability. The company's revenue forecast is high at 57.31% annual growth, but consistent losses raise questions about its path to sustained profitability. While the stock's P/S ratio is higher than industry peers, its DCF fair value suggests significant upside, creating a polarized view on its valuation.
Ideaya Biosciences Inc - Enters Sales Agreement With Jefferies For Common Stock Offering Up To $350 Million - SEC Filing
Ideaya Biosciences Inc. has announced a sales agreement with Jefferies for a common stock offering. The offering is for up to $350 million. This information was disclosed in an SEC filing.
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates
IDEAYA Biosciences, Inc. (IDYA) reported a wider-than-expected loss for the first quarter of 2024, missing revenue estimates. The company posted a net loss of $0.51 per share, compared to analyst predictions of a $0.48 loss. Revenue for the quarter was $2.0 million, falling short of the estimated $6.4 million.
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences announced its first-quarter 2026 financial results and provided a comprehensive business update, highlighted by positive topline data from the OptimUM-02 trial, leading to planned NDA submission for darovasertib. The company is advancing several oncology pipeline programs, including IDE849 and IDE034, with numerous clinical updates and trial initiations anticipated in the second half of 2026. IDEAYA reported approximately $973 million in cash, cash equivalents, and marketable securities as of March 31, 2026, maintaining its cash runway guidance into 2030.
IDEAYA (NASDAQ: IDYA) renews shelf, keeps $156.6M ATM capacity
IDEAYA Biosciences (NASDAQ: IDYA) has renewed its automatic shelf registration statement on Form S-3ASR and filed an at-the-market prospectus supplement, maintaining its capacity to sell up to $156.6 million in common stock. This new filing replaces a prior shelf registration set to expire in June 2026, and the company has already sold over $193 million under the existing Open Market Sales Agreement with Jefferies LLC. The remaining capacity allows IDEAYA flexibility for future discretionary sales to raise capital.
IDEAYA Biosciences Files New Shelf Registration Statement
IDEAYA Biosciences (IDYA) has filed a new automatic shelf registration statement on Form S-3ASR to replace an expiring one, maintaining its financial flexibility for equity financing. The company preserved approximately $156.6 million in at-the-market capacity. Spark, TipRanks’ AI Analyst, rates IDYA as Neutral, noting strong balance sheet positioning but persistent losses and weak cash flow.
IDEAYA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
IDEAYA Biosciences Inc (IDYA) reported its earnings for the quarter ended March 31. The summary indicates that this is a brief financial announcement from the company.
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences announced positive first-quarter 2026 financial results and provided a business update, highlighting that the Phase 2/3 registrational trial for darovasertib combination met its primary endpoint, leading to plans for a New Drug Application (NDA) submission in the second half of 2026. The company also reported approximately $973 million in cash reserves and outlined upcoming clinical updates and trials for its diversified oncology pipeline, including IDE849, IDE034, and IDE574. IDEAYA emphasized its strategic focus on precision medicine oncology and its strong financial position to advance its product candidates.
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, Vs. FactSet Est of $5.0M
IDEAYA Biosciences, Inc. (IDYA) announced its first-quarter revenue of $6.6 million, significantly surpassing the FactSet estimate of $5.0 million. This financial beat indicates a stronger-than-anticipated performance for the biotechnology company during the reported quarter.
IDEAYA says eye cancer drug combo cut progression risk 58%
IDEAYA Biosciences announced positive topline results for its eye cancer drug combination, darovasertib, which reduced the risk of disease progression by 58% in a Phase 2/3 trial. This breakthrough paves the way for a New Drug Application (NDA) submission to the FDA in the second half of 2026 under the Real-Time Oncology Review (RTOR) program. The company also reported strong financials with $972.9 million in cash, providing a runway into 2030, despite increased R&D expenses and a widened net loss.
IDEAYA (IDYA) posts Q1 2026 loss, advances darovasertib NDA plan
IDEAYA Biosciences reported an increased net loss of $98.5 million for Q1 2026, despite growing collaboration revenue. The company announced positive Phase 2/3 results for its drug darovasertib in metastatic uveal melanoma, leading to plans for an NDA filing in H2 2026 under the FDA's Real-Time Oncology Review program. IDEAYA maintains a strong cash position of $972.9 million, providing a cash runway into 2030, and is advancing several other oncology pipeline programs while reprioritizing some assets.
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, vs. FactSet Est of $5.0M
IDEAYA Biosciences, Inc. (IDYA) announced its Q1 revenue reached $6.6 million, surpassing the FactSet estimate of $5.0 million. This financial update follows previous reports of the company's Q1 loss of $1.11 per share against an estimated loss of $1.05 per share. The company is actively moving darovasertib towards FDA review following positive trial readouts.
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences reported positive topline data from its Phase 2/3 OptimUM-02 trial, leading to plans for an NDA submission for darovasertib combination in metastatic uveal melanoma. The company also provided updates on other product candidates, including IDE849 and IDE034, and announced its financial results for the first quarter of 2026. IDEAYA Biosciences holds approximately $973 million in cash and marketable securities and expects a cash runway into 2030.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced inducement grants under Nasdaq Listing Rule 5635(c)(4). This information was delivered by Quantisnow, a real-time market data and news platform. Quantisnow aggregates various financial data for retail investors, including press releases, SEC filings, and analyst ratings.
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following FDA Real-Time Review Of Darovasertib NDA
IDEAYA Biosciences (IDYA) recently announced the FDA will review its NDA for darovasertib for metastatic uveal melanoma under the Real-Time Oncology Review program, following positive Phase 2/3 trial results. This is a significant regulatory milestone that could shift the investment narrative, moving focus from clinical uncertainty to execution risk for the company's lead drug. Despite this positive development, the article notes that investors still need to consider IDEAYA's substantial cash burn, ongoing losses, and the stock's potentially overvalued status.
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following FDA Real-Time Review Of Darovasertib NDA
IDEAYA Biosciences announced that the FDA will review its New Drug Application for darovasertib for metastatic uveal melanoma under the Real-Time Oncology Review program, following positive Phase 2/3 trial results. This could shift the investment narrative from clinical uncertainty to execution risk, although the company continues to face substantial cash burn with profitability not expected soon. Investors should consider the reliance on future commercialization and funding for its broad pipeline.
Technical Reactions to IDYA Trends in Macro Strategies
The article analyzes Ideaya Biosciences Inc. (NASDAQ: IDYA) through algorithmic analysis, identifying weak near and mid-term sentiment but a strong long-term outlook. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—alongside support and resistance levels across different time horizons. The analysis emphasizes the importance of institutional trading strategies, risk management, and AI-generated signals for informed decision-making.
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
LifeSci Capital has reiterated its Buy rating on IDEAYA Biosciences (IDYA.US), maintaining a target price of $62. This indicates a positive outlook on the company's future stock performance and financial health.
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
IDEAYA Biosciences announced that the FDA has agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib for patients with first-line HLA*A2-negative metastatic uveal melanoma (mUM) under the Real-Time Oncology Review (RTOR) program. The decision follows positive topline data from the Phase 2/3 OptimUM-02 trial, which met its primary endpoint by significantly improving progression-free survival. The company plans to initiate the RTOR submission process in May, with the full NDA filing expected in the second half of 2026, aiming to expedite the availability of this potential new treatment.
Five new IDEAYA hires receive stock options at $29.10 a share
IDEAYA Biosciences granted 237,800 non-qualified stock options to five new employees on April 30, 2026, under its 2023 Inducement Plan. The options have an exercise price of $29.10 per share, matching the closing price on the grant date, and will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) for hiring inducements and applies to individuals not previously employed by the company.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced it granted non-qualified stock options for 237,800 shares to five new employees on April 30, 2026. These grants, made under the 2023 Employment Inducement Incentive Award Plan, serve as material inducements for their employment with IDEAYA, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $29.10 per share and will vest over four years.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced it granted non-qualified stock options to purchase 237,800 shares of common stock to five new employees. These grants were made under the company's 2023 Employment Inducement Incentive Award Plan, per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $29.10 per share, a 10-year term, and vest over four years.
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA significantly reduced its stake in IDEAYA Biosciences (NASDAQ:IDYA) by 28.9% in the fourth quarter, selling 298,664 shares. Despite this, IDEAYA Biosciences reported strong quarterly earnings, beating analyst expectations for both EPS and revenue, with revenue increasing 55.7% year-over-year. Institutional ownership in the company remains high at 98.29%, and analysts maintain a "Moderate Buy" rating with an average price target of $50.44.
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
IDEAYA Biosciences announced that the FDA has agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib for patients with first-line HLA*A2-negative metastatic uveal melanoma. This review will be conducted under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program. The company is a precision medicine oncology firm, and its stock symbol is IDYA.
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
IDEAYA Biosciences announced that the FDA will review its New Drug Application (NDA) for darovasertib in combination with crizotinib for metastatic uveal melanoma under the Real-Time Oncology Review (RTOR) program. This decision follows positive topline data from the Phase 2/3 OptimUM-02 trial, which met its primary endpoint by significantly reducing disease progression. The company plans to initiate the RTOR submission process in May, with the full NDA filing anticipated in the second half of 2026.
FDA accepts IDEAYA rare eye cancer drug for real-time review
IDEAYA Biosciences (NASDAQ: IDYA) announced that the FDA has accepted its New Drug Application (NDA) for darovasertib in combination with crizotinib for first-line metastatic uveal melanoma into the Real-Time Oncology Review (RTOR) program. This follows positive Phase 2/3 OptimUM-02 trial results, which met its primary endpoint by significantly improving progression-free survival. The company plans to initiate the RTOR submission in May, with full NDA completion expected in the second half of 2026, aiming for an expedited review process.
Executive pay and auditor vote headline IDEAYA (NASDAQ: IDYA) 2026 meeting
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its 2026 virtual annual shareholder meeting will be held on June 16, 2026, at 1:30 p.m. Pacific Time. Shareholders will vote on electing three Class I directors, ratifying PricewaterhouseCoopers LLP as the independent auditor for 2026, and a non-binding advisory resolution on executive compensation. The board recommends voting "FOR" all three proposals, and as of April 20, 2026, 87,860,920 shares of common stock are outstanding and eligible to vote.
Ideaya Biosciences gets coverage initiation at Barclays and Citizens
Ideaya Biosciences (NASDAQ:IDYA) has received new coverage initiations from two financial institutions, Barclays and Citizens. Barclays assigned an "Overweight" rating with a price target of $46, while Citizens also initiated coverage with an "Outperform" rating and a target of $48. These initiations suggest a positive outlook from both firms regarding Ideaya's stock performance.
RBC Capital Maintains IDEAYA Biosciences (IDYA) Outperform Recommendation
This article states that RBC Capital has reiterated its "Outperform" rating for IDEAYA Biosciences (IDYA). The firm also maintained its price target of $62.00 for the company. This suggests a continued positive outlook from RBC Capital regarding IDYA's stock performance.
Ideaya Biosciences gets coverage initiation at Barclays and Citizens
This article reports that Ideaya Biosciences has received coverage initiation from two major financial institutions, Barclays and Citizens. This development could signal increased analyst interest and potentially impact the company's stock visibility and investor sentiment.
IDYA Price Today: IDEAYA Biosciences, Inc. Stock Price, Quote & Chart | MEXC
This article provides current stock information for IDEAYA Biosciences, Inc. (IDYA) on MEXC, including its latest price, market data, and recent performance trends. It also offers details about the company's oncology-focused precision medicine approach, its clinical-stage product candidates, and instructions on how to buy IDYA stock on the MEXC platform. Additionally, the article addresses frequently asked questions regarding IDYA's stock performance, valuation, and financial reporting.
IDEAYA Biosciences Advances Precision Oncology with AI Discovery
IDEAYA Biosciences (IDYA) is strengthening its position in the biotechnology sector, specializing in synthetic lethality-based cancer therapies. Wedbush Securities increased its price target for IDEAYA from $52 to $58 following positive Phase 2/3 OptimUM-02 trial results. The company is also advancing its IDE574 program, an early-stage clinical trial for a first-in-class small-molecule therapy targeting epigenetic markers critical for cancer cell survival, and uses AI for drug discovery.
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout
Wedbush Securities has increased its price target for IDEAYA Biosciences (IDYA) from $52 to $58, maintaining an Outperform rating, following positive top-line results from the company’s Phase 2/3 OptimUM-02 clinical trial. The company also announced the initiation of patient enrollment for a Phase 1 study of IDE574, a novel epigenetic therapy targeting advanced solid tumors. IDEAYA Biosciences focuses on AI-driven precision oncology, developing targeted cancer treatments based on synthetic lethality.
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5% - Here's Why
IDEAYA Biosciences (NASDAQ:IDYA) saw its share price drop by 4.5% during mid-day trading on Tuesday, with significantly reduced trading volume. Despite this dip, analysts remain largely bullish on the stock, with a "Moderate Buy" consensus rating and an average target price of $50.44. The company has recently surpassed quarterly earnings and revenue estimates, and an insider purchased 50,000 shares in early March.
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Mel
IDEAYA Biosciences will present complete data from its Phase 2/3 registrational trial (OptimUM-02) of darovasertib in combination with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma at the 2026 ASCO Annual Meeting. The presentation will include detailed and additional data not previously disclosed, with Dr. Marlana Orloff presenting the primary results. IDEAYA is an oncology company focused on developing precision medicines for cancer.
